Abstract
Non-alcoholic steatohepatitis (NASH) is a liver disease in which fatty infiltration is accompanied by liver inflammation. GSK3008356 is under development as a selective inhibitor of diacylglycerol acyltransferase 1 (DGAT1), a key enzyme involved in the formation of triglyceride (TG). Decreased DGAT1 activity can reduce circulating TG and liver TG, and therefore could potentially prevent or treat NASH. The aim of the current study was to develop a population pharmacokinetic-pharmacodynamic (PKPD) model that characterizes the PK disposition of GSK3008356 and its relation to the changes in blood TG. Drug concentrations were measured in 104 healthy adults receiving various single (SD) and repeat doses (RD) in a first time in human (FiH) study. A 30% fat meal was given at hour 2 postdose, and blood postprandial TG concentrations were measured at various time points. The population PKPD model consists of several parts including a PK model, drug effect model, meal effect model, and a turnover model. The pharmacokinetic data were described using a 3-compartment model. Drug effect was described by an inhibitory sigmoidal Emax model. Since TG levels change with the introduction of a meal, a bi-exponential meal effect model was utilized. ...Continue Reading
References
Feb 1, 1979·Annals of the Rheumatic Diseases·T GibsonH A Simmonds
Mar 1, 1988·JPEN. Journal of Parenteral and Enteral Nutrition·U Julius, W Leonhardt
Apr 17, 1982·British Medical Journal·J L DayC N Simpson
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·S CasesR V Farese
Nov 24, 1999·The American Journal of Medicine·G MarchesiniN Melchionda
Jul 10, 2002·Gastroenterology·Elisabetta BugianesiMario Rizzetto
Jun 12, 2003·JAMA : the Journal of the American Medical Association·Jeanne M Clark, Anna Mae Diehl
Mar 1, 2005·Basic & Clinical Pharmacology & Toxicology·Mats O KarlssonRujia Xie
May 5, 2006·Fundamental & Clinical Pharmacology·Demiana William FaltaosPhilippe Lechat
Aug 2, 2007·Nature Clinical Practice. Gastroenterology & Hepatology·Clare Nugent, Zobair M Younossi
Nov 15, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kanji YamaguchiAnna Mae Diehl
Sep 2, 2008·Journal of Lipid Research·Chi-Liang Eric YenRobert V Farese
Oct 29, 2008·Seminars in Liver Disease·Mariana Lazo, Jeanne M Clark
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Apr 11, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Naga ChalasaniArun J Sanyal
Jan 5, 2014·CPT: Pharmacometrics & Systems Pharmacology·R N Upton, D R Mould
Apr 10, 2015·Journal of Clinical Pharmacology·Charles D MeyersJin Chen
May 6, 2015·British Journal of Clinical Pharmacology·Jennifer Q DongRoberto A Calle
Jun 10, 2015·JAMA : the Journal of the American Medical Association·Mary E Rinella
Oct 7, 2016·Acta Pharmaceutica Sinica. B·Xi-Ling JiangAi-Ming Yu
Apr 7, 2017·Journal of Lipid Research·Jörn JaskolowskiMads F Hjorth
Nov 12, 2018·Journal of Hepatology·Zobair M Younossi